Cargando…
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
BACKGROUND: Multiple myeloma (MM) is the second most common hematologic malignancy. Aberrant epigenetic modifications have been reported in MM and could be promising therapeutic targets. As response rates are overall limited but deep responses occur, it is important to identify those patients who co...
Autores principales: | Bruyer, Angelique, Maes, Ken, Herviou, Laurie, Kassambara, Alboukadel, Seckinger, Anja, Cartron, Guillaume, Rème, Thierry, Robert, Nicolas, Requirand, Guilhem, Boireau, Stéphanie, Müller-Tidow, Carsten, Veyrune, Jean-luc, Vincent, Laure, Bouhya, Salahedine, Goldschmidt, Hartmut, Vanderkerken, Karin, Hose, Dirk, Klein, Bernard, De Bruyne, Elke, Moreaux, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931098/ https://www.ncbi.nlm.nih.gov/pubmed/29500406 http://dx.doi.org/10.1038/s41416-018-0025-x |
Ejemplares similares
-
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018) -
CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017) -
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019) -
Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020) -
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)